Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Gamma-Hydroxybutyric acid Stories

2012-07-19 14:21:29

HAMPTON, Va. and DUBLIN, July 19, 2012 /PRNewswire/ -- Patient Advocate Foundation (PAF) and Jazz Pharmaceuticals (Nasdaq: JAZZ)have partnered to launch the Narcolepsy CareLine, a dedicated hotline (866-538-7617) providing support services to the narcolepsy patient community. The hotline is staffed by a team of professionals from PAF, a national non-profit organization with experience in customized patient-focused case management. Narcolepsy is a chronic neurologic brain disorder caused...

New Brain Receptor For Drug Fantasy Identified
2012-07-03 06:16:59

Connie K. Ho for redOrbit.com — Your Universe Online Alcohol and drugs are just a few of the things that can possibly be found at play in a nightclub. Scientists from the University of Copenhagen (UC) recently studied the effects of a particular drug called Fantasy. With their studies, the UC researchers revealed that they were able to gain a better understanding of the biological makeup of gamma-hydroxbutryic acid (GHB,) a transmitter substance found in the brain. GHB is related...

2012-03-22 02:24:18

WASHINGTON and DUBLIN, March 22, 2012 /PRNewswire/ -- Wake Up Narcolepsy and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) have teamed up with professional golfer, Nicole Jeray to launch the 2012 Swinging for Sleep online fundraising campaign. The campaign raises funds to support narcolepsy awareness, research and patient support programs through nonprofit organizations dedicated to the narcolepsy community. To view the multimedia assets associated with this release, please click...

2011-04-26 00:00:28

Following the death of her son, Julius, to the highly addictive bodybuilding/club drug GHB (gamma hydroxy butyrate), Suki deJong directed and produced the film All Apologies to increase awareness of GHB, commonly known as the "date-rape" drug. All Apologies, a short (22-min.) documentary, has been re-mastered and updated to spread the word about this insidious drug. (PRWEB) April 25, 2011 April 22, 2011 - Boynton Beach, Florida - Following the death of her son, Julius, to the highly...

2010-12-21 15:05:00

PALO ALTO, Calif., Dec. 21, 2010 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Xyrem® (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy." The new patent, number 7,851,506, is also listed in the FDA's Approved Drug Products List (the Orange Book). In addition...

2010-10-20 07:00:00

SAN DIEGO, Oct. 20, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy. The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 1 mg, 3 mg and 5 mg single doses of APD916. The trial evaluated 24 healthy volunteers...

6a2f97c1c3ebf6350c461c4c86f737051
2010-08-22 10:55:00

A Food and Drug Administration (FDA) advisory panel on Friday significantly rejected the application of Jazz Pharmaceuticals for the approval of Xyrem (sodium oxybate) for the treatment of fibromyalgia.The drug is chemically similar to GHB -- the "date-rape" drug. Approving the drug for such a large patient population would risk flooding the streets with a pharmaceutical-grade version of the highly controlled substance."Sodium oxybate and GHB are the same thing," said Lewis Nelson, MD, of the...

2010-06-24 15:30:00

PALO ALTO, Calif., June 24 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee will review JZP-6 (sodium oxybate) for the treatment of fibromyalgia at a joint meeting on August 20, 2010. In February 2010, the FDA accepted for filing and review the New Drug Application (NDA) of JZP-6 (sodium oxybate) for the treatment of...

2010-03-24 07:00:00

SAN DIEGO, March 24, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy. "There is a need for better tolerated, more effective therapies for narcolepsy, especially narcolepsy with cataplexy," said William R. Shanahan, M.D., Arena's Vice President...

2010-02-18 16:00:00

PALO ALTO, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia. Based on a standard 10-month review, the target date for the FDA to complete its review of the NDA under the Prescription Drug User Fee Act (PDUFA) is October 11, 2010. The submission is based on a comprehensive...